{"entity":{"id":"oncternal-therapeutics","kind":"company","name":"Oncternal Therapeutics","aka":["Oncternal Therapeutics, Inc.","GTx","NASDAQ:ONCT"],"tldr":"Oncternal Therapeutics is a San Diego biotech that developed the ROR1 antibody zilovertamab, licensed to Merck as an antibody-drug conjugate, and TK216, a small molecule against the EWS-FLI1 fusion that drives Ewing sarcoma.","summary":"Oncternal Therapeutics, formed by the 2019 merger with GTx, developed zilovertamab (cirmtuzumab), a ROR1 antibody studied with ibrutinib in mantle cell lymphoma and chronic lymphocytic leukaemia; the antibody became the basis of Merck's antibody-drug conjugate zilovertamab vedotin. TK216, an inhibitor of the EWS-FLI1 oncoprotein, was tested with vincristine in relapsed Ewing sarcoma. Its later programmes were a ROR1 CAR-T and the androgen receptor antagonist ONCT-534; in 2025 the company discontinued development and moved to wind down.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.oncternal.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tk216"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.oncternal.com/","ticker":"NASDAQ:ONCT","investors":[],"funding":[]},"route":"/companies/oncternal-therapeutics/","neighbours":{"drug":[{"id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/"}]}}